Application of Wild Macrofungi as Anticancer Therapeutics

Cheong, Peter Chiew Hing; Tan, Cher Siang; Fung, Shin Yee

doi:10.1007/978-3-030-02622-6_12

Cited by 2 publications

(3 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of mushroom as medicine is common in the Oriental culture. Several biopharmacological properties from edible and wild mushroom species have been recognized and registered as anticancer therapeutics following positive results from clinical trials . The search is now striding toward finding bioactive compounds from medicinal mushrooms that are selective in their cytotoxicity, targeting only cancerous cells, and with minimal harming effect on normal healthy cells.…”

Section: Discussionmentioning

confidence: 99%

“…Several biopharmacological properties from edible and wild mushroom species have been recognized and registered as anticancer therapeutics following positive results from clinical trials. 42 The search is now striding toward finding bioactive compounds from medicinal mushrooms that are selective in their cytotoxicity, targeting only cancerous cells, and with minimal harming effect on normal healthy cells. Burgeoning evidences on lectins impeding or inhibiting cancer growth 24 are encouraging, and provide the rational to search for anticancer lectins in rare mushrooms used in folk medicine such as the TMM L. rhinocerus.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cloning, overexpression, purification, and modeling of a lectin (Rhinocelectin) with antiproliferative activity from Tiger Milk Mushroom, Lignosus rhinocerus

et al. 2019

View full text Add to dashboard Cite

A lectin gene from the Tiger Milk Mushroom Lignosus rhinocerus TM02® was successfully cloned and expressed via vector pET28a in Escherichia coli BL21(DE3). The recombinant lectin, Rhinocelectin, with a predicted molecular mass of 22.8 kDa, was overexpressed in water‐soluble form without signal peptide and purified via native affinity chromatography Ni‐NTA agarose. Blast protein analysis indicated the lectin to be homologous to jacalin‐related plant lectin. In its native form, Rhinocelectin exists as a homo‐tetramer predicted with four chains of identical proteins consisting of 11 beta‐sheet structures with only one alpha‐helix structure. The antiproliferative activity of the Rhinocelectin against human cancer cell lines was concentration dependent and selective. The IC50 values against triple negative breast cancer cell lines MDA‐MB‐231 and breast cancer MCF‐7 are 36.52 ± 13.55 μg mL−1 and 53.11 ± 22.30 μg mL−1, respectively. Rhinocelectin is only mildly cytotoxic against the corresponding human nontumorigenic breast cell line 184B5 with IC50 value at 142.19 ± 36.34 μg mL−1. The IC50 against human lung cancer cell line A549 cells is 46.14 ± 7.42 μg mL−1 while against nontumorigenic lung cell line NL20 is 41.33 ± 7.43 μg mL−1. The standard anticancer drug, Doxorubicin exhibited IC50 values mostly below 1 μg mL−1 for the cell lines tested. Flow cytometry analysis showed the treated breast cancer cells were arrested at G0/G1 phase and apoptosis induced. Rhinocelectin agglutinated rat and rabbit erythrocytes at a minimal concentration of 3.125 μg mL−1 and 6.250 μg mL−1, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cloning, overexpression, purification, and modeling of a lectin (Rhinocelectin) with antiproliferative activity from Tiger Milk Mushroom, Lignosus rhinocerus

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many biologically active secondary metabolites with anti-tumor activities have been investigated from mushrooms. The growth of several types of tumors like Sarcoma 37 , Sarcoma 180 solid tumor, Ehrlich solid tumor, Lewis lung carcinoma and Yoshida sarcoma were inhibited by polysaccharides produced by mushrooms 54,55 . For the very first time in 1960s, anti-tumor activity of mushroom polysaccharide lentinan was reported 56 .…”

Section: Anti-tumor and Anti-cancer Activitiesmentioning

confidence: 99%

Untitled

2021

IJPSR

View full text Add to dashboard Cite

Since ancient times, humans have always been captivated by nature and have explored natural products. To combat against novel emerging and reemerging diseases and tremendous side effects imposed by recent therapies, scientists have again taken an interest in natural resources. To date, plants have been the major source of natural bioactive compounds, but recently fungi have got more attention. Amongst fungi, edible and medicinal mushrooms have come out as a rich source of bioactive metabolites. Since long back, they are being consumed heavily because of their outstanding flavour, aroma, nutritional value, and medicinal properties. Both edible, as well as medicinal mushrooms, synthesize bioactive compounds known as secondary metabolites i.e., polysaccharides, steroids, terpenes as well as peptides. Such metabolites possess many medicinal properties like anti-oxidant, anti-tumor, anti-diabetic, anti-cancer, antiageing, and also anti-obesity. Furthermore, mushroom secondary metabolites are prioritized over other natural compounds due to their non-toxic nature and low or no side effects. This review mainly covers sources and types of secondary mushroom metabolites and their therapeutic applications.

show abstract

Application of Wild Macrofungi as Anticancer Therapeutics

Cited by 2 publications

References 123 publications

Cloning, overexpression, purification, and modeling of a lectin (Rhinocelectin) with antiproliferative activity from Tiger Milk Mushroom, Lignosus rhinocerus

Cloning, overexpression, purification, and modeling of a lectin (Rhinocelectin) with antiproliferative activity from Tiger Milk Mushroom, Lignosus rhinocerus

Untitled

Contact Info

Product

Resources

About